Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
And may not be able to afford it -especially early in the benefit year
In November 2023, a version of the drug was approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition
Reducing exposure while maintaining effectiveness represents a reasonable risk reduction strategy for those concerned about theoretical cancer risk
International Journal of Pharmacology
Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells
US$ 27.28
US$ 25.90
US$ 26.46
US$ 24.09
